WO2008019276A2 - Solid forms of (3'-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone and methods of their use - Google Patents
Solid forms of (3'-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone and methods of their use Download PDFInfo
- Publication number
- WO2008019276A2 WO2008019276A2 PCT/US2007/075022 US2007075022W WO2008019276A2 WO 2008019276 A2 WO2008019276 A2 WO 2008019276A2 US 2007075022 W US2007075022 W US 2007075022W WO 2008019276 A2 WO2008019276 A2 WO 2008019276A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methanone
- pyrimidin
- chlorobiphenyl
- piperidin
- crystalline
- Prior art date
Links
- 239000007787 solid Substances 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 29
- VHTIWIZIPOXSNP-UHFFFAOYSA-N [4-(3-chlorophenyl)phenyl]-(1-pyrimidin-2-ylpiperidin-4-yl)methanone Chemical compound ClC1=CC=CC(C=2C=CC(=CC=2)C(=O)C2CCN(CC2)C=2N=CC=CN=2)=C1 VHTIWIZIPOXSNP-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
- 201000010099 disease Diseases 0.000 claims description 26
- 239000002552 dosage form Substances 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 18
- -1 3'-chlorobiphenyl-4-yl Chemical group 0.000 claims description 17
- 238000002441 X-ray diffraction Methods 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims description 10
- 230000003931 cognitive performance Effects 0.000 claims description 9
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 9
- 206010012289 Dementia Diseases 0.000 claims description 8
- 208000020358 Learning disease Diseases 0.000 claims description 6
- 201000007201 aphasia Diseases 0.000 claims description 6
- 201000003723 learning disability Diseases 0.000 claims description 6
- 208000000044 Amnesia Diseases 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 206010003805 Autism Diseases 0.000 claims description 4
- 208000020706 Autistic disease Diseases 0.000 claims description 4
- 201000002882 Agraphia Diseases 0.000 claims description 3
- 206010049669 Dyscalculia Diseases 0.000 claims description 3
- 208000026139 Memory disease Diseases 0.000 claims description 3
- 208000014604 Specific Language disease Diseases 0.000 claims description 3
- 208000005028 anomia Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 206010058319 dysgraphia Diseases 0.000 claims description 3
- 206010013932 dyslexia Diseases 0.000 claims description 3
- 230000015654 memory Effects 0.000 claims description 3
- 230000006984 memory degeneration Effects 0.000 claims description 3
- 208000023060 memory loss Diseases 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 238000001237 Raman spectrum Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 8
- 208000037765 diseases and disorders Diseases 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 9
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 108010007439 proline transporter Proteins 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- SDEAGACSNFSZCU-UHFFFAOYSA-N (3-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1 SDEAGACSNFSZCU-UHFFFAOYSA-N 0.000 description 3
- NVAKSNKROARJQQ-UHFFFAOYSA-N (4-bromophenyl)-piperidin-4-ylmethanone Chemical compound C1=CC(Br)=CC=C1C(=O)C1CCNCC1 NVAKSNKROARJQQ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- NCSBCBVKUJQIKJ-UHFFFAOYSA-N [4-(3-chlorophenyl)phenyl]-piperidin-4-ylmethanone;hydrochloride Chemical compound Cl.ClC1=CC=CC(C=2C=CC(=CC=2)C(=O)C2CCNCC2)=C1 NCSBCBVKUJQIKJ-UHFFFAOYSA-N 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 238000005079 FT-Raman Methods 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 206010014666 Endocarditis bacterial Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 1
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010027236 Meningitis fungal Diseases 0.000 description 1
- 206010027259 Meningitis tuberculous Diseases 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 108060007766 SLC6A7 Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000037132 Subdural Chronic Hematoma Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000022971 Tuberculous meningitis Diseases 0.000 description 1
- 206010046326 Uraemic encephalopathy Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 208000009361 bacterial endocarditis Diseases 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000003083 communicating hydrocephalus Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 208000017004 dementia pugilistica Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 201000010056 fungal meningitis Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000001223 meningeal tuberculosis Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 208000002040 neurosyphilis Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- This invention relates to amorphous and crystalline solid forms of (3'- chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone, and to methods of their use.
- the amorphous form of a drug may exhibit different dissolution characteristics and different bioavailability patterns than its crystalline form(s), properties which can affect how the drug must be administered to achieve optimal effect.
- Amorphous and crystalline forms of a drug may also have different handling properties (e.g., flowability, compressibility), dissolution rates, solubilities and stabilities, all of which can affect the manufacture of dosage forms. Consequently, access to multiple forms of a drug is desirable for a variety of reasons.
- regulatory authorities e.g., the U.S. Food and Drug Administration
- This invention is directed, in part, to amorphous and crystalline solid forms of (3'- chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone, which is an inhibitor of the Na + -dependent proline transporter.
- One embodiment of the invention encompasses pharmaceutical compositions comprising the solid forms described herein.
- Another embodiment encompasses methods of improving cognitive performance, and of treating, managing and/or preventing various diseases and disorders, using solid forms of the invention.
- Figure 1 is a X-ray diffraction pattern of a crystalline solid form of (3'- chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone.
- the spectrum was obtained using a Shimadzu XRD-6000 diffractometer configured as follows: X-ray tube[Cu (1.54060 A), 40.0 kV, 40.0 niA]; scan range [3.00 to 45.0 degrees, 0.0400 degree step size]; count time [1.20 sec].
- Figure 2 is a FT-Raman spectrum of a crystalline solid form of (3'-chlorobiphenyl- 4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone.
- the spectrum was obtained using a Bruker RFSlOO spectrometer: 1064 nm excitation (100 mW); 64 scans.
- This invention is directed, in part, to solid amorphous and crystalline forms of (3'- chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone, which is an inhibitor of the Na + -dependent proline transporter.
- solid amorphous and crystalline forms of (3'- chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone which is an inhibitor of the Na + -dependent proline transporter.
- This invention is also directed to dosage forms comprising solid amorphous and crystalline forms of (3 '-chlorobiphenyl-4-yl)( 1 -(pyrimidin-2-yl)piperidin-4-yl)methanone, and to methods of using solid amorphous and crystalline forms of (3'-chlorobiphenyl-4- yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone for the improvement of cognitive performance and for the treatment, prevention and/or management of diseases and disorders such as Alzheimer's disease, autism, cognitive disorders, dementia, learning disorders, and short- and long-term memory loss.
- the terms “manage,” “managing” and “management” encompass preventing the recurrence of the specified disease or disorder, or of one or more of its symptoms, in a patient who has already suffered from the disease or disorder, and/or lengthening the time that a patient who has suffered from the disease or disorder remains in remission.
- the terms encompass modulating the threshold, development and/or duration of the disease or disorder, or changing the way that a patient responds to the disease or disorder.
- the terms “prevent,” “preventing” and “prevention” contemplate an action that occurs before a patient begins to suffer from the specified disease or disorder, which inhibits or reduces the severity of the disease or disorder, or of one or more of its symptoms.
- the terms encompass prophylaxis.
- a prophylactically effective amount of a compound is an amount sufficient to prevent a disease or condition, or one or more symptoms associated with the disease or condition, or to prevent its recurrence.
- a prophylactically effective amount of a compound is an amount of therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the disease or condition.
- the term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
- a "therapeutically effective amount" of a compound is an amount sufficient to provide a therapeutic benefit in the treatment or management of a disease or condition, or to delay or minimize one or more symptoms associated with the disease or condition.
- a therapeutically effective amount of a compound is an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment or management of the disease or condition.
- the term "therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of a disease or condition, or enhances the therapeutic efficacy of another therapeutic agent.
- the terms “treat,” “treating” and “treatment” contemplate an action that occurs while a patient is suffering from the specified disease or disorder, which reduces the severity of the disease or disorder, or one or more of its symptoms, or retards or slows the progression of the disease or disorder.
- the term “include” has the same meaning as “include, but are not limited to,” and the term “includes” has the same meaning as “includes, but is not limited to.”
- the term “such as” has the same meaning as the term “such as, but not limited to.”
- one or more adjectives immediately preceding a series of nouns is to be construed as applying to each of the nouns.
- any atom shown in a drawing with unsatisfied valences is assumed to be attached to enough hydrogen atoms to satisfy the valences.
- chemical bonds depicted with one solid line parallel to one dashed line encompass both single and double (e.g., aromatic) bonds, if valences permit. Structures that represent compounds with one or more chiral centers, but which do not indicate stereochemistry (e.g.
- One embodiment is directed to a solid amorphous form. Another is directed to a solid crystalline form.
- a particular crystalline form of the compound has a melting point of about 117 0 C
- the form provides a X-ray diffraction pattern that contains peaks at about 4.7, 9.3, 18.8, 19.7, 22.4, 23.2, 27.9, 29.6, 32.3, 32.6, 37.2, 41.5, 42.3, and/or 42.7 degrees 2 ⁇ .
- the relative intensities of peaks in a X-ray diffraction pattern of a crystalline form can vary depending on how the sample is prepared and how the data is collected.
- an example of a X-ray diffraction pattern of this crystalline form is provided in Figure 1.
- An example of an FT-Raman spectrum of this crystalline form is provided in Figure 2.
- This particular crystalline form can be prepared by: dissolving 3'-chlorobiphenyl- 4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone in ethanol (e.g., at a temperature greater than room temperature) to provide a solution; cooling the solution (or allowing the solution to cool) to a temperature at which crystalline 3'-chlorobiphenyl-4-yl)(l- (pyrimidin-2-yl)piperidin-4-yl)methanone forms; and isolating the crystalline 3'- chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone.
- This invention encompasses solids that are mixtures of both amorphous and crystalline forms. Certain such solids comprise crystalline (3'-chlorobiphenyl-4-yl)(l- (pyrimidin-2-yl)piperidin-4-yl)methanone in an amount of at least about 50, 75, 80, 85, 90, 95 or 99 weight percent.
- One embodiment of this invention encompasses a method of inhibiting a pro line transporter, which comprises contacting a proline transporter (in vitro or in vivo) with a sufficient amount of a compound of the invention (i.e. a compound disclosed herein).
- a proline transporter in vitro or in vivo
- Preferred proline transporters are encoded by the human gene SLC6A7, the murine ortholog thereof, or a nucleic acid molecule that encodes a proline transporter and that hybridizes under standard conditions to the full length of either.
- Another embodiment encompasses a method of improving the cognitive performance of a human patient, which comprises administering to the patient an effective amount of a compound of the invention.
- improved cognitive performance include enhanced learning (e.g., learning more quickly), improved comprehension, improved reasoning, and improved short- and/or long-term memory.
- Another embodiment encompasses a method of treating, managing or preventing a cognitive disorder (e.g. , difficulty in thinking, reasoning, or problem solving), memory loss (short- and long-term), or a learning disorder (e.g. , dyslexia, dyscalculia, dysgraphia, dysphasia, dysnomia), which comprises administering to the patient an effective amount of a compound of the invention.
- a cognitive disorder e.g. , difficulty in thinking, reasoning, or problem solving
- memory loss short- and long-term
- a learning disorder e.g. , dyslexia, dyscalculia, dysgraphia, dysphasia, dysnomia
- Another embodiment encompasses a method of treating, managing or preventing a disease or disorder, or a cognitive impairment associated therewith, in a human patient, which comprises administering to the patient a therapeutically or prophylactically effective amount of a compound of the invention.
- diseases and disorders include age-associated memory impairment, Alzheimer's disease, Attention- Deficit/Hyperactivity Disorder (ADD/ ADHD), autism, Down syndrome, Fragile X syndrome, Huntington's disease, Parkinson's disease, and schizophrenia. Additional disorders include adverse sequelae of brain damage caused by, for example, oxygen starvation, traumatic injury, heart attack or stroke.
- the invention also encompasses methods of treating, preventing and managing dementia, including dementia associated with metabolic-toxic, structural and/or infectious causes.
- Metabolic-toxic causes of dementia include: anoxia; Bi 2 deficiency; chronic drug, alcohol or nutritional abuse; folic acid deficiency; hypercalcemia associated with hyperparathyroidism; hypoglycemia; hypothyroidism; organ system failure (e.g. , hepatic, respiratory, or uremic encephalopathy); and pellagra.
- Structural causes of dementia include: amyotrophic lateral sclerosis; brain trauma (e.g., chronic subdural hematoma, dementia pugilistica); brain tumors; cerebellar degeneration; communicating hydrocephalus; irradiation to frontal lobes; multiple sclerosis; normal-pressure hydrocephalus; Pick's disease; progressive multifocal leukoencephalopathy; progressive supranuclear palsy; surgery; vascular disease (e.g. , multi-infarct dementia); and Wilson's disease.
- Infectious causes of dementia include: bacterial endocarditis; Creutzfeldt- Jakob disease; Gerstmann-Straussler-Scheinker disease; HIV-related disorders; neurosyphilis; tuberculous and fungal meningitis; and viral encephalitis.
- Example dosing regimens include: 150, 600 and 1200 mg/day by oral administration.
- compositions and dosage forms comprising solid form of the invention.
- Pharmaceutical compositions and dosage forms of this invention may optionally contain one or more pharmaceutically acceptable carriers or excipients.
- Certain pharmaceutical compositions are single unit dosage forms suitable for oral, topical, mucosal (e.g. , nasal, pulmonary, sublingual, vaginal, buccal, or rectal), parenteral (e.g., subcutaneous, intravenous, bolus injection, intramuscular, or intraarterial), or transdermal administration to a patient.
- dosage forms include, but are not limited to: tablets; caplets; capsules, such as soft elastic gelatin capsules; cachets; troches; lozenges; dispersions; suppositories; ointments; cataplasms (poultices); pastes; powders; dressings; creams; plasters; solutions; patches; aerosols (e.g., nasal sprays or inhalers); gels; liquid dosage forms suitable for oral or mucosal administration to a patient, including suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or a water-in-oil liquid emulsions), solutions, and elixirs; liquid dosage forms suitable for parenteral administration to a patient; and sterile solids (e.g., crystalline or amorphous solids) that can be reconstituted to provide liquid dosage forms suitable for parenteral administration to a patient.
- suspensions e.g., aqueous
- the formulation should suit the mode of administration.
- oral administration may require enteric coatings to protect the active ingredient from degradation within the gastrointestinal tract.
- the active ingredient may be administered in a liposomal formulation to shield it from degradative enzymes, facilitate transport in circulatory system, and/or effect delivery across cell membranes to intracellular sites.
- composition, shape, and type of dosage forms of the invention will typically vary depending on their use.
- a dosage form used in the acute treatment of a disease may contain larger amounts of one or more of the active ingredients it comprises than a dosage form used in the chronic treatment of the same disease.
- a parenteral dosage form may contain smaller amounts of one or more of the active ingredients it comprises than an oral dosage form used to treat the same disease.
- the compound (3'-chloro-biphenyl-4-yl)-(l-pyrimidin-2-yl-piperidin-4-yl)- methanone was prepared from an intermediate, (3'-chloro-biphenyl-4-yl)-piperidine-4-yl- methanone hydrochloride, as described below. 6.1. Preparation of (3 '-C hlor o-biphenyl-4-yl)-piperidine-4-yl-methanone hydrochloride
- 3-Chlorophenyl boronic acid (Alfa Aesar, purity 97%)(40.7g, 261.19 mmol, 1.4 eq) was dissolved in isopropanol (Aldrich, ACS reagent grade) (800 ml) under nitrogen atmosphere. This was added to a solution of aqueous potassium carbonate (77 g in 150 ml water), bis(triphenylphosphine)palladium(II) dichloride (PdCl 2 (PPh 3 )2) (0.65g, 0.93 mmol, 0.5 mol.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Solid amorphous and crystalline forms of (3'-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone are disclosed, in addition to methods of their use in the treatment of various diseases and disorders.
Description
SOLID FORMS OF (3'-CHLOROBIPHENYL-4-YL)q-(PYRIMIDIN-2- YDPIPERIDIN-4- YDMETHANONE AND METHODS OF THEIR USE
This application claims priority to U.S. provisional patent application no. 60/835,677, filed August 4, 2006, the entirety of which is incorporated herein by reference.
1. FIELD OF THE INVENTION
This invention relates to amorphous and crystalline solid forms of (3'- chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone, and to methods of their use.
2. BACKGROUND OF THE INVENTION
Different solid forms of the same compound can have substantially different properties. For example, the amorphous form of a drug may exhibit different dissolution characteristics and different bioavailability patterns than its crystalline form(s), properties which can affect how the drug must be administered to achieve optimal effect. Amorphous and crystalline forms of a drug may also have different handling properties (e.g., flowability, compressibility), dissolution rates, solubilities and stabilities, all of which can affect the manufacture of dosage forms. Consequently, access to multiple forms of a drug is desirable for a variety of reasons. Moreover, regulatory authorities (e.g., the U.S. Food and Drug Administration) may require the identification of all solid forms of a new drug substance before approving products containing it. A. Goho, Science News 166(8):122-123 (2004).
Compounds may exist in one or more crystalline forms, but their existence and characteristics cannot be predicted with any certainty. In addition, no standard procedure exists for the preparation of all possible polymorphic forms of a compound. And even after one polymorph has been identified, the existence and characteristics of other forms can only be determined by additional experimentation. Id.
3. SUMMARY OF THE INVENTION
This invention is directed, in part, to amorphous and crystalline solid forms of (3'- chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone, which is an inhibitor of the Na+-dependent proline transporter.
One embodiment of the invention encompasses pharmaceutical compositions comprising the solid forms described herein.
Another embodiment encompasses methods of improving cognitive performance, and of treating, managing and/or preventing various diseases and disorders, using solid forms of the invention.
4. BRIEF DESCRIPTION OF THE FIGURES
Certain aspects of the invention may be understood with reference to the attached figures.
Figure 1 is a X-ray diffraction pattern of a crystalline solid form of (3'- chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone. The spectrum was obtained using a Shimadzu XRD-6000 diffractometer configured as follows: X-ray tube[Cu (1.54060 A), 40.0 kV, 40.0 niA]; scan range [3.00 to 45.0 degrees, 0.0400 degree step size]; count time [1.20 sec].
Figure 2 is a FT-Raman spectrum of a crystalline solid form of (3'-chlorobiphenyl- 4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone. The spectrum was obtained using a Bruker RFSlOO spectrometer: 1064 nm excitation (100 mW); 64 scans.
5. DETAILED DESCRIPTION OF THE INVENTION
This invention is directed, in part, to solid amorphous and crystalline forms of (3'- chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone, which is an inhibitor of the Na+-dependent proline transporter. See U.S. patent application nos. 11/433,057 and 11/433,626, both filed May 12, 2006. When administered to mice, the compound has been shown to increase learning and memory.
This invention is also directed to dosage forms comprising solid amorphous and crystalline forms of (3 '-chlorobiphenyl-4-yl)( 1 -(pyrimidin-2-yl)piperidin-4-yl)methanone, and to methods of using solid amorphous and crystalline forms of (3'-chlorobiphenyl-4- yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone for the improvement of cognitive performance and for the treatment, prevention and/or management of diseases and disorders such as Alzheimer's disease, autism, cognitive disorders, dementia, learning disorders, and short- and long-term memory loss.
5.1. Definitions
Unless otherwise indicated, the terms "manage," "managing" and "management" encompass preventing the recurrence of the specified disease or disorder, or of one or more of its symptoms, in a patient who has already suffered from the disease or disorder, and/or lengthening the time that a patient who has suffered from the disease or disorder remains in remission. The terms encompass modulating the threshold, development and/or duration of the disease or disorder, or changing the way that a patient responds to the disease or disorder.
Unless otherwise indicated, the terms "prevent," "preventing" and "prevention" contemplate an action that occurs before a patient begins to suffer from the specified disease or disorder, which inhibits or reduces the severity of the disease or disorder, or of one or more of its symptoms. The terms encompass prophylaxis.
Unless otherwise indicated, a "prophylactically effective amount" of a compound is an amount sufficient to prevent a disease or condition, or one or more symptoms associated with the disease or condition, or to prevent its recurrence. A prophylactically effective amount of a compound is an amount of therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the disease or condition. The term "prophylactically effective amount" can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
Unless otherwise indicated, a "therapeutically effective amount" of a compound is an amount sufficient to provide a therapeutic benefit in the treatment or management of a disease or condition, or to delay or minimize one or more symptoms associated with the disease or condition. A therapeutically effective amount of a compound is an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment or management of the disease or condition. The term "therapeutically effective amount" can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of a disease or condition, or enhances the therapeutic efficacy of another therapeutic agent. Unless otherwise indicated, the terms "treat," "treating" and "treatment" contemplate an action that occurs while a patient is suffering from the specified disease or disorder, which reduces the severity of the disease or disorder, or one or more of its symptoms, or retards or slows the progression of the disease or disorder.
Unless otherwise indicated, the term "include" has the same meaning as "include, but are not limited to," and the term "includes" has the same meaning as "includes, but is not limited to." Similarly, the term "such as" has the same meaning as the term "such as, but not limited to." Unless otherwise indicated, one or more adjectives immediately preceding a series of nouns is to be construed as applying to each of the nouns. For example, the phrase "optionally substituted alky, aryl, or heteroaryl" has the same meaning as "optionally substituted alky, optionally substituted aryl, or optionally substituted heteroaryl." It should also be noted that any atom shown in a drawing with unsatisfied valences is assumed to be attached to enough hydrogen atoms to satisfy the valences. In addition, chemical bonds depicted with one solid line parallel to one dashed line encompass both single and double (e.g., aromatic) bonds, if valences permit. Structures that represent compounds with one or more chiral centers, but which do not indicate stereochemistry (e.g. , with bolded or dashed lines), encompasses pure stereoisomers and mixtures (e.g., racemic mixtures) thereof. Similarly, names of compounds having one or more chiral centers that do not specify the stereochemistry of those centers encompass pure stereoisomers and mixtures thereof.
5.2. Forms of (3 '-Chlorobiphenyl-4-yl)( l-( pyrimidin-2-yl)piperidin-4- vDmethanone This invention is directed to solid forms of (3'-chlorobiphenyl-4-yl)(l-(pyrimidin-
2-yl)piperidin-4-yl)methanone, the structure of which is depicted below:
One embodiment is directed to a solid amorphous form. Another is directed to a solid crystalline form. A particular crystalline form of the compound has a melting point of about 117 0C
(e.g. , ± 1.50C) as determined by DSC. The form provides a X-ray diffraction pattern that contains peaks at about 4.7, 9.3, 18.8, 19.7, 22.4, 23.2, 27.9, 29.6, 32.3, 32.6, 37.2, 41.5, 42.3, and/or 42.7 degrees 2Θ. As those skilled in the art are well aware, the relative intensities of peaks in a X-ray diffraction pattern of a crystalline form can vary depending
on how the sample is prepared and how the data is collected. With this in mind, an example of a X-ray diffraction pattern of this crystalline form is provided in Figure 1. An example of an FT-Raman spectrum of this crystalline form is provided in Figure 2.
This particular crystalline form can be prepared by: dissolving 3'-chlorobiphenyl- 4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone in ethanol (e.g., at a temperature greater than room temperature) to provide a solution; cooling the solution (or allowing the solution to cool) to a temperature at which crystalline 3'-chlorobiphenyl-4-yl)(l- (pyrimidin-2-yl)piperidin-4-yl)methanone forms; and isolating the crystalline 3'- chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone. This invention encompasses solids that are mixtures of both amorphous and crystalline forms. Certain such solids comprise crystalline (3'-chlorobiphenyl-4-yl)(l- (pyrimidin-2-yl)piperidin-4-yl)methanone in an amount of at least about 50, 75, 80, 85, 90, 95 or 99 weight percent.
5.3. Methods of Treatment One embodiment of this invention encompasses a method of inhibiting a pro line transporter, which comprises contacting a proline transporter (in vitro or in vivo) with a sufficient amount of a compound of the invention (i.e. a compound disclosed herein). Preferred proline transporters are encoded by the human gene SLC6A7, the murine ortholog thereof, or a nucleic acid molecule that encodes a proline transporter and that hybridizes under standard conditions to the full length of either.
Another embodiment encompasses a method of improving the cognitive performance of a human patient, which comprises administering to the patient an effective amount of a compound of the invention. Examples of improved cognitive performance include enhanced learning (e.g., learning more quickly), improved comprehension, improved reasoning, and improved short- and/or long-term memory.
Another embodiment encompasses a method of treating, managing or preventing a cognitive disorder (e.g. , difficulty in thinking, reasoning, or problem solving), memory loss (short- and long-term), or a learning disorder (e.g. , dyslexia, dyscalculia, dysgraphia, dysphasia, dysnomia), which comprises administering to the patient an effective amount of a compound of the invention.
Another embodiment encompasses a method of treating, managing or preventing a disease or disorder, or a cognitive impairment associated therewith, in a human patient, which comprises administering to the patient a therapeutically or prophylactically
effective amount of a compound of the invention. Examples of diseases and disorders include age-associated memory impairment, Alzheimer's disease, Attention- Deficit/Hyperactivity Disorder (ADD/ ADHD), autism, Down syndrome, Fragile X syndrome, Huntington's disease, Parkinson's disease, and schizophrenia. Additional disorders include adverse sequelae of brain damage caused by, for example, oxygen starvation, traumatic injury, heart attack or stroke.
The invention also encompasses methods of treating, preventing and managing dementia, including dementia associated with metabolic-toxic, structural and/or infectious causes. Metabolic-toxic causes of dementia include: anoxia; Bi2 deficiency; chronic drug, alcohol or nutritional abuse; folic acid deficiency; hypercalcemia associated with hyperparathyroidism; hypoglycemia; hypothyroidism; organ system failure (e.g. , hepatic, respiratory, or uremic encephalopathy); and pellagra.
Structural causes of dementia include: amyotrophic lateral sclerosis; brain trauma (e.g., chronic subdural hematoma, dementia pugilistica); brain tumors; cerebellar degeneration; communicating hydrocephalus; irradiation to frontal lobes; multiple sclerosis; normal-pressure hydrocephalus; Pick's disease; progressive multifocal leukoencephalopathy; progressive supranuclear palsy; surgery; vascular disease (e.g. , multi-infarct dementia); and Wilson's disease. Infectious causes of dementia include: bacterial endocarditis; Creutzfeldt- Jakob disease; Gerstmann-Straussler-Scheinker disease; HIV-related disorders; neurosyphilis; tuberculous and fungal meningitis; and viral encephalitis.
The amount of solid form administered to a patient will depend on the route of administration and on the condition being treated, managed or prevented, and can be readily determined by physicians. Example dosing regimens include: 150, 600 and 1200 mg/day by oral administration.
5.4. Pharmaceutical Compositions
This invention encompasses pharmaceutical compositions and dosage forms comprising solid form of the invention. Pharmaceutical compositions and dosage forms of this invention may optionally contain one or more pharmaceutically acceptable carriers or excipients. Certain pharmaceutical compositions are single unit dosage forms suitable for oral, topical, mucosal (e.g. , nasal, pulmonary, sublingual, vaginal, buccal, or rectal), parenteral (e.g., subcutaneous, intravenous, bolus injection, intramuscular, or
intraarterial), or transdermal administration to a patient. Examples of dosage forms include, but are not limited to: tablets; caplets; capsules, such as soft elastic gelatin capsules; cachets; troches; lozenges; dispersions; suppositories; ointments; cataplasms (poultices); pastes; powders; dressings; creams; plasters; solutions; patches; aerosols (e.g., nasal sprays or inhalers); gels; liquid dosage forms suitable for oral or mucosal administration to a patient, including suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or a water-in-oil liquid emulsions), solutions, and elixirs; liquid dosage forms suitable for parenteral administration to a patient; and sterile solids (e.g., crystalline or amorphous solids) that can be reconstituted to provide liquid dosage forms suitable for parenteral administration to a patient.
The formulation should suit the mode of administration. For example, oral administration may require enteric coatings to protect the active ingredient from degradation within the gastrointestinal tract. In another example, the active ingredient may be administered in a liposomal formulation to shield it from degradative enzymes, facilitate transport in circulatory system, and/or effect delivery across cell membranes to intracellular sites.
The composition, shape, and type of dosage forms of the invention will typically vary depending on their use. For example, a dosage form used in the acute treatment of a disease may contain larger amounts of one or more of the active ingredients it comprises than a dosage form used in the chronic treatment of the same disease. Similarly, a parenteral dosage form may contain smaller amounts of one or more of the active ingredients it comprises than an oral dosage form used to treat the same disease. These and other ways in which specific dosage forms encompassed by this invention will vary from one another will be readily apparent to those skilled in the art. See, e.g. , Remington 's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton PA (1990).
6. EXAMPLES
The compound (3'-chloro-biphenyl-4-yl)-(l-pyrimidin-2-yl-piperidin-4-yl)- methanone was prepared from an intermediate, (3'-chloro-biphenyl-4-yl)-piperidine-4-yl- methanone hydrochloride, as described below.
6.1. Preparation of (3 '-C hlor o-biphenyl-4-yl)-piperidine-4-yl-methanone hydrochloride
(3'-Chloro-biphenyl-4-yl)-piperidine-4-yl-methanone hydrochloride was prepared by three different methods, identified below as A, B and C. Method A:
3-Chlorophenyl boronic acid (Alfa Aesar, purity 97%)(40.7g, 261.19 mmol, 1.4 eq) was dissolved in isopropanol (Aldrich, ACS reagent grade) (800 ml) under nitrogen atmosphere. This was added to a solution of aqueous potassium carbonate (77 g in 150 ml water), bis(triphenylphosphine)palladium(II) dichloride (PdCl2(PPh3)2) (0.65g, 0.93 mmol, 0.5 mol. eq.) and (4-bromophenyl)(piperidine-4-yl)methanone (50 g, 187 mmol, 1 eq) were stirred at 8O0C for three hours and deemed complete by LC/MS. After the reaction mixture cooled down to 5O0C, it was filtered through celite pad, washed with methanol (1 liter). The filtrate was diluted with water (200 ml), then the organic solvent removed under reduced pressure. The resulting crude product was dissolved in ethyl acetate (800 ml) and washed with IN sodium hydroxide (2 x 40ml) and water (1 x 40 ml).
The organic layer was stirred with aqueous lactic acid (64g of 85% lactic acid in 600ml of water) at 5O0C for 20 minutes. After the organic layer was separated (solution assay indicated 8% of product present in the organic layer, which can be captured by additional lactic acid extraction), the aqueous layer was washed with ethyl acetate (2 x 100 ml). The aqueous layer was separated, basified to pH=l 1 with 25% NaOH (-70 ml), and then extracted with ethyl acetate (2 x 200 ml), dried over sodium sulfate, filtered and concentrated under reduced pressure to obtained biaryl product 46.23g (83%) as a syrup. HPLC indicated 99.4% product and 0.57% of debrominated staring material.
The above product was dissolved in mixture of ethyl acetate (900 ml) and ethanol (45 ml) and heated at 5O0C. 6M aq. HCl (40 ml) was added dropwise over a period often minutes. After 20 minutes, the reaction mixture was cooled to room temperature, and stirring was continued for an additional hour. The resulting white solid was filtered and dried under vacuum at 5O0C for five hours to afford 49.8 grams of the biaryl HCl salt (80%). HPLC indicated pure product. 1H NMR (DMSO-de) δ: 1.92(m,4H), 2.52(m,2H), 3.12(m, 2H), 3.82(m,lH),
7.51(m,2H),7.75 (m,lH), 7.82(br s,lH), 7.92(bs d, 2H), 8.12(brd, 2H), 9.0 (br s, 2H). MH+ = 300, 302 (about 3:1). Pd: 15 ppm.
Method B
A round bottom flask was charged with (4-bromophenyl)(piperidine-4- yl)methanone (20.0 g, 74.6 mmol), 3-chlorophenyl boronic acid (17.4 g, 111 mmol, 1.5 eq), and palladium encapsulated catalyst (Aldrich, Pd EnCat-TPP®, catalyst species PdCl2(PPhS)2) (5.2 g, 0.187 mmol, 0.05 eq). These solids were suspended in isopropanol (570 ml) and allowed to stir for five minutes. To the mixture was added potassium carbonate (30.8 g, 224 mmol, 3 eq) dissolved in H2O (30 ml). The reaction mixture was heated to 8O0C for 16 hours and deemed complete by LC/MS. The suspension was filtered through a small bed of Celite® and the filtrate was concentrated to dryness. The resulting solids were dissolved in isopropyl acetate (400 ml) and washed with water (3 x 75 ml). The organic layer was then cooled to O0C (ice/water bath) and to this stirring solution was added slowly 6 N HCl until solids crystalized. The solids were filtered and dried in a vacuum oven for 16 hours at 5O0C to afford 16.9 g of compound (68% yield) in > 98% HPLC purity. MH+ = 300, 302 (about 3:1). Pd=3ppm.
Method C
A round bottom flask was charged with (4-bromophenyl)(piperidine-4- yl)methanone (4.00 g, 14.9 mmol), 3-chlorophenyl boronic acid (3.26 g, 20.9 mmol, 1.4 eq), and Fibrecat 1029® (0.70 g, 0.448 mmol, 0.03 eq, Johnson Matthey). These solids were suspended in isopropanol (68 ml) and allowed to stir for five minutes. To this stirring solution was added potassium carbonate (6.18 g, 44.8 mmol, 3 eq.) dissolved in H2O (12 ml). The resulting solution was heated to 8O0C for 16 hours, at which time the reaction was deemed complete by LC/MS. The reaction mixture was filtered through a small bed of Celite® and the filtrate was concentrated to dryness. The resulting solids were dissolved in isopropyl acetate (100 ml) and washed with water (3 x 50 ml). The organics were cooled to O0C, and to this stirring mixture was added slowly 6N HCl until solids crashed out of solution. The solids were filtered and dried for 16 hours at 5O0C in a vacuum oven to afford 2.89g of compound (72%) in > 98% HPLC purity. MH+ = 300, 302 (about 3:1). Pd: 4ppm
6.2. Preparation of (T-Chloro-biphenyl-4-yl)-Q-pyrimidin-2yl-piperidine-
4-yl)-methanone
A mixture of (3'-chloro-biphenyl-4-yl)-piperidine-4-yl-methanone hydrochloride salt (4Og, 119.4 mmol), 2-chloropyrimidine (19 g, 167.16 mmol, 1.4 eq), potassium
carbonate (325 mesh, Aldrich ) (49.4 g, 358.2 mmol, 3 eq) and acetonitrile (560 ml) were stirred at 6O0C for 14 hours and deemed complete by LC/MS. The reaction mixture was concentrated, and the residue was dissolved in ethyl acetate (800 ml) and water (200 ml). The aqueous layer was separated and extracted with ethyl acetate (I x 200 ml). The organic layers were combined and washed with brine (1 x 50 ml), dried and concentrated.
6.3. Crystallization of (3f-Chloro-biphenyl-4-yl)-(l-pyrimidin-2yl- piperidine-4-yl)-methanone
The product obtained as described in Example 2 was taken into ethanol (700 ml) and stirred with a mechanical stirrer at 7O0C. After 30 minutes, the solid was completely dissolved. At that time, the reaction temperature was decreased to 450C and stirred for 4 hours (heterogeneous mixture). The reaction mixture was then stirred at room temperature for 3 hours. The resulting white solid was filtered washed with ethanol (50 ml), dried at 5O0C for 5 hours. This gave the product in 84.4% yield (33.9g) as a white solid. 100% pure by HPLC . 1H NMR(CDCl3) δ: 1.75(m,2H), 1.92(m,2H), 3.05(m,2H), 3.50(m,lH),
4.75(m,2H), 6.42(t,lH), 7.32(m,2H), 7.4(m,lH), 7.51(s,lH),7.62(d,2H), 7.95(d,2H), 8.22(d,2H). 13CNMR(CDCl3): 28.72, 43.79,44.34, 110.2, 125.82, 127.78, 127.81, 128.63, 129.39, 130.62, 135.29, 135.49, 142.03, 144.62, 158.13, 161.93, 202.09. MH+ = 378, 380 (about 3:1 ratio). Pd: 2 ppm.
All patents and patent applications cited above are incorporated herein by reference in their entireties. The full scope of the invention is understood with reference to the appended claims.
Claims
1. Solid amorphous (3'-chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4- yl)methanone or a pharmaceutically acceptable salt or solvate thereof.
2. A pharmaceutical dosage form comprising the solid of claim 1.
3. The dosage form of claim 2, which is a single unit dosage form.
4. The single unit dosage form of claim 3, which is a capsule or tablet.
5. A method of improving the cognitive performance of a patient, which comprises administering to the patient an effective amount of the solid of claim 1.
6. The method of claim 5, wherein the cognitive performance is rapidity of learning, comprehension, reasoning, or memory.
7. A method of treating, managing or preventing a disease or disorder in a patient, which comprises administering to the patient an effective amount of the solid of claim 1.
8. The method of claim 7, wherein the disease or disorder is Alzheimer's disease, autism, a cognitive disorder, dementia, a learning disorder, or memory loss.
9. The method of claim 8, wherein the learning disorder is dyslexia, dyscalculia, dysgraphia, dysphasia, or dysnomia.
10. Crystalline (3'-chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4- yl)methanone or a pharmaceutically acceptable salt or solvate thereof.
11. A crystalline form of (3'-chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin- 4-yl)methanone having an X-ray diffraction pattern that comprises a peak at about 4.7 degrees 2Θ.
12. The crystalline form of claim 11 , wherein the X-ray diffraction pattern further comprises peaks at about 9.3 and 18.8 degrees 2Θ.
13. The crystalline form of claim 11 , wherein the X-ray diffraction pattern further comprises peaks at about 19.7 and 22.4 degrees 2Θ.
14. The crystalline form of claim 11 , wherein the X-ray diffraction pattern further comprises peaks at about 23.2 and 27.9 degrees 2Θ.
15. The crystalline form of claim 11 , wherein the X-ray diffraction pattern further comprises peaks at about 29.6 and 32.2 degrees 2Θ.
16. The crystalline form of claim 11 , wherein the X-ray diffraction pattern further comprises peaks at about 32.6 and 37.2 degrees 2Θ.
17. The crystalline form of claim 11 , wherein the X-ray diffraction pattern further comprises peaks at about 41.6 and 42.3 degrees 2Θ.
18. The crystalline form of claim 11 , wherein the X-ray diffraction pattern further comprises peaks at about 9.3, 27.9 and 42.7 degrees 2Θ.
19. A crystalline form of (3'-chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin- 4-yl)methanone having a X-ray diffraction pattern that is substantially the same as that shown in Figure 1.
20. A crystalline form of (3'-chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin- 4-yl)methanone having a Raman spectrum that is substantially the same as that shown in
Figure 2.
21. A crystalline form of (3'-chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin- 4-yl)methanone having a melting point of about 117°C.
22. Solid 3'-chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone comprising crystalline 3'-chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4- yl)methanone in an amount of at least about 50 weight percent.
23. The solid of claim 22, which comprises crystalline 3'-chlorobiphenyl-4- yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone in an amount of at least about 75 weight percent.
24. The solid of claim 23, which comprises crystalline 3'-chlorobiphenyl-4- yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone in an amount of at least about 95 weight percent.
25. A method of preparing crystalline 3'-chlorobiphenyl-4-yl)(l-(pyrimidin-2- yl)piperidin-4-yl)methanone, which comprises: dissolving 3 '-chlorobiphenyl-4-yl)( 1 -(pyrimidin-2-yl)piperidin-4-yl)methanone in ethanol to provide a solution; cooling the solution to a temperature at which crystalline 3'-chlorobiphenyl-4- yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone forms; and isolating the crystalline 3'-chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4- yl)methanone.
26. A pharmaceutical dosage form comprising crystalline (3'-chlorobiphenyl- 4-yl)( 1 -(pyrimidin-2-yl)piperidin-4-yl)methanone.
27. The dosage form of claim 26, wherein the crystalline (3'-chlorobiphenyl-4- yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone has a X-ray diffraction pattern containing a peak at about 9.3 degrees 2Θ.
28. The dosage form of claim 26, which is a single unit dosage form.
29. The single unit dosage form of claim 28, which is a capsule or tablet.
30. A method of improving the cognitive performance of a patient, which comprises administering to the patient an effective amount of crystalline (3'- chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone.
31. A method of improving the cognitive performance of a patient, which comprises administering to the patient an effective amount of the crystalline form of claim 11.
32. The method of claim 30 or 31 , wherein the cognitive performance is rapidity of learning, comprehension, reasoning, or memory.
33. A method of treating, managing or preventing a disease or disorder in a patient, which comprises administering to the patient an effective amount of crystalline
(3'-chlorobiphenyl-4-yl)(l-(pyrimidin-2-yl)piperidin-4-yl)methanone.
34. A method of treating, managing or preventing a disease or disorder in a patient, which comprises administering to the patient an effective amount of the crystalline form of claim 11.
35. The method of claim 33 or 34, wherein the disease or disorder is Alzheimer's disease, autism, a cognitive disorder, dementia, a learning disorder, or memory loss.
36. The method of claim 35, wherein the learning disorder is dyslexia, dyscalculia, dysgraphia, dysphasia, or dysnomia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07813677A EP2086547A2 (en) | 2006-08-04 | 2007-08-02 | Solid forms of (3'-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone and methods of their use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83567706P | 2006-08-04 | 2006-08-04 | |
US60/835,677 | 2006-08-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008019276A2 true WO2008019276A2 (en) | 2008-02-14 |
WO2008019276A3 WO2008019276A3 (en) | 2008-03-20 |
Family
ID=38859037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/075022 WO2008019276A2 (en) | 2006-08-04 | 2007-08-02 | Solid forms of (3'-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone and methods of their use |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080076788A1 (en) |
EP (1) | EP2086547A2 (en) |
AR (1) | AR062204A1 (en) |
TW (1) | TW200815400A (en) |
WO (1) | WO2008019276A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009006255A1 (en) * | 2007-06-28 | 2009-01-08 | Lexicon Pharmaceuticals, Inc. | Particulate (3'-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone and methods of its use |
WO2019046303A1 (en) * | 2017-08-28 | 2019-03-07 | The Trustees Of Columbia University In The City Of New York | A method for predicting a subject's response to slc modulator therapy |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2084144B1 (en) | 2006-08-04 | 2011-02-23 | Lexicon Pharmaceuticals, Inc. | Synthesis of piperazines, piperidines and related compounds |
TW200827345A (en) * | 2006-11-07 | 2008-07-01 | Lexicon Pharmaceuticals Inc | (R)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their use |
TW200823193A (en) * | 2006-11-07 | 2008-06-01 | Lexicon Pharmaceuticals Inc | (S)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their use |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040127501A1 (en) * | 2002-09-24 | 2004-07-01 | Zhengming Chen | Therapeutic agents useful for treating pain |
WO2006124897A2 (en) * | 2005-05-13 | 2006-11-23 | Lexicon Genetics Incorporated | Methods and compositions for improving cognition |
-
2007
- 2007-08-02 US US11/832,728 patent/US20080076788A1/en not_active Abandoned
- 2007-08-02 WO PCT/US2007/075022 patent/WO2008019276A2/en active Application Filing
- 2007-08-02 EP EP07813677A patent/EP2086547A2/en not_active Withdrawn
- 2007-08-02 TW TW096128449A patent/TW200815400A/en unknown
- 2007-08-03 AR ARP070103432A patent/AR062204A1/en unknown
Non-Patent Citations (1)
Title |
---|
None |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009006255A1 (en) * | 2007-06-28 | 2009-01-08 | Lexicon Pharmaceuticals, Inc. | Particulate (3'-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone and methods of its use |
WO2019046303A1 (en) * | 2017-08-28 | 2019-03-07 | The Trustees Of Columbia University In The City Of New York | A method for predicting a subject's response to slc modulator therapy |
Also Published As
Publication number | Publication date |
---|---|
AR062204A1 (en) | 2008-10-22 |
TW200815400A (en) | 2008-04-01 |
WO2008019276A3 (en) | 2008-03-20 |
EP2086547A2 (en) | 2009-08-12 |
US20080076788A1 (en) | 2008-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101644657B1 (en) | Solids forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate | |
AU2014239995B2 (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
US20150344488A1 (en) | Solid forms of an antiviral compound | |
CN112437765A (en) | Salt forms of bipedac acid and methods of use thereof | |
EA021753B1 (en) | 3-({[3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepine-8-yl]methyl}amino)pentanedioic acid | |
JP2006518360A (en) | Method for producing imatinib and imatinib produced by the method | |
EP2635563B1 (en) | Crystalline forms of hydrochloride salt of (4a-r,9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1h-indeno [2,1-b]pyridine-6-carbonitrile and their use as hsd 1 inhibitors | |
US20080076788A1 (en) | Solid forms of (3'-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone and methods of their use | |
US20090099206A1 (en) | Solid forms of (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use | |
EP1861391B1 (en) | Methods for preparing substituted sulfoxide compounds | |
JP5247687B2 (en) | Crystalline duloxetine hydrochloride | |
US10351574B2 (en) | Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same | |
US8975405B2 (en) | Indenopyridine derivatives | |
SG189535A1 (en) | Crystalline forms of ( s ) - 2 - amino - 3 - (4 - ( 2 - amino - 6 - ( (r) - 1 - (4 - ch loro-2-(3 -methyl- 1h- pyrazol- 1 -yl) phenyl) - 2, 2, 2 - trifluoroethoxy) pyrimidin- 4 - yl) phenyl) propanoic acid | |
US8143409B2 (en) | Crystalline form of rabeprazole sodium | |
KR102160841B1 (en) | 2-pyridone compound | |
US20090005407A1 (en) | Particulate (3'-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone and methods of its use | |
JP5017274B2 (en) | S-omeprazole strontium salt or hydrate thereof, process for producing the same, and pharmaceutical composition containing the same | |
KR101098031B1 (en) | Novel crystalline form of amlodipine nicotinate and its preparation method | |
WO2024153856A1 (en) | Process for the preparation of 3-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)pyridine 1-oxide | |
TW202411215A (en) | Method for preparation of 6-methoxypyridine-3-yl derivatives | |
CN117321054A (en) | Crystalline forms of tricyclic derivative compounds, methods of preparing the same and pharmaceutical compositions containing the same | |
CN102176910A (en) | A new crystalline form of 4- (5- { (IR) -1- [5- (3- chlorophenyl) isoxazol-3-yl] ethoxy } -4-methyl-4H-l, 2, 4- triazol-3-yl) pyridine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07813677 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007813677 Country of ref document: EP |